Latest Articles

Publication Date
Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer - Pharmacy Times

Impact of Overall Survival Data on Immunotherapy Selection in Endometrial Cancer Pharmacy Times

Published: April 17, 2026, 12:30 p.m.
Navigating the Clinical and Economic Burden of Endometrial Cancer - Pharmacy Times

Navigating the Clinical and Economic Burden of Endometrial Cancer Pharmacy Times

Published: April 17, 2026, 12:30 p.m.
A Chemo-Free Option for Some Advanced Endometrial Cancers? - Medscape

A Chemo-Free Option for Some Advanced Endometrial Cancers? Medscape

Published: April 17, 2026, 11:26 a.m.
Doctor Calls Bispecific Results “Phenomenal” in Advanced Endometrial Cancer Trial - CU Anschutz newsroom

Doctor Calls Bispecific Results “Phenomenal” in Advanced Endometrial Cancer Trial CU Anschutz newsroom

Published: April 16, 2026, 11:26 p.m.
GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer - medscape.com

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer medscape.com

Published: April 16, 2026, 12:45 p.m.
GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer - Medscape

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer Medscape

Published: April 16, 2026, 12:45 p.m.
Trial Marks “Major Step in Progress in Endometrial Cancer Research” - Oncology News Central

Trial Marks “Major Step in Progress in Endometrial Cancer Research” Oncology News Central

Published: April 16, 2026, 10:14 a.m.
Endometrial Cancer Staging Updates Reflect Molecular Profiling - Cleveland Clinic

Endometrial Cancer Staging Updates Reflect Molecular Profiling Cleveland Clinic

Published: April 16, 2026, 5:42 a.m.
BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - BioPharm International

BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer BioPharm International

Published: April 15, 2026, 10:02 p.m.
REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer - CancerNetwork

REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer CancerNetwork

Published: April 14, 2026, 8:09 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!